Rapid Micro Biosystems has raised $25 million in Series C equity financing. The financing will be used to expand global commercial and manufacturing operations in support of the industry leading Growth Direct^TM System across the applications of environmental monitoring, sterility and bioburden testing.

The round included financing from new investors, Hepalink USA Inc. and Richard K. Mellon and Sons, along with continued participation from Kleiner Perkins Caufield & Byers, Longitude Capital, Quaker Partners, TPG Biotech, and TVM Capital.

The Growth Direct^TM System is the only system on the market where all the quality control applications can be run both concurrently and automatically on a single instrument. The system provides results starting within just hours; sending problem alerts so that decision-making and remedial action can begin immediately. Leveraging an already proven detection technology, the Growth Direct^TM System delivers exceptional enhancements to productivity, faster response time and reduction in errors.

“Since the commercial launch of the next generation Growth Direct™ System last year, we have seen tremendous positive response from the world’s leading pharmaceutical, personal care and medical device companies,” said Robert Spignesi, President and CEO. “This additional investment will fuel our strategic expansion plans.”

For more information about Rapid Micro Biosystems visit www.rapidmicrobio.com